Brief: Rubius Therapeutics Presents Initial Clinical Results From The Ongoing Phase 1/2 Clinical Trial Of RTX-240
09/04/2021 13:41
April 9 (Reuters) - Rubius Therapeutics Inc RUBY.O :
* RUBIUS THERAPEUTICS PRESENTS INITIAL CLINICAL RESULTS FROM
THE
ONGOING PHASE 1/2 CLINICAL TRIAL OF RTX-240 IN ADVANCED SOLID
TUMORS AT THE AMERICAN ASSOCIATION OF CANCER RESEARCH VIRTUAL
ANNUAL MEETING
* RUBIUS THERAPEUTICS - INTEND TO INITIATE NEW PHASE 1 ARM
TO
EVALUATE RTX-240 IN COMBINATION WITH ANTI-PD-1 THERAPY DURING H2
2021
Source text for Eikon: ID:nGNX4Q2VKl
Further company coverage: RUBY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rubius Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Apple, TCR2 Therapeutics, Silvergate Capital
Brief: Rubius Therapeutics Inc - Nasdaq Notified Co That Trading In Co's Stock Will Be Suspended Upon Opening Of Business On March 7, 2023
Brief: Rubius Therapeutics Board Of Directors Approved Plan Of Liquidation And Dissolution Of Company
Rubius Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Baidu, Boeing, Microsoft